Ensuring enantiomeric consistency in FAPI radiopharmaceuticals: comparative analysis of (S)- and (S/R)-FAPI-46/-74 confirms pharmacological equivalence

Key Points

• To investigate the pharmacological equivalence of (S)- and (S/R)-FAPI-46/-74 radiopharmaceuticals.
• Conducted comparative analysis between (S)- and (S/R)-FAPI-46/-74
• Assessed pharmacokinetic and pharmacodynamic behavior
• Used statistical methods for validation
• (S/R)-mixtures exhibited comparable pharmacokinetics to pure (S)-enantiomers
• Pharmacodynamics of (S/R)-mixtures were similar to pure (S)-enantiomers
• Findings support regulatory confidence in clinical applications of FAPI-46/-74